Background: The long-term natural history and impact of irritable bowel syndrome (IBS)-type symptoms on outcomes in inflammatory bowel disease (IBD) are uncertain.
Aim: To assess this in a longitudinal follow-up study of patients in secondary care METHODS: We assessed the natural history of IBS-type symptoms in IBD via Rome III criteria applied at baseline, and 2 and 6 years. We defined longitudinal disease activity as the need for glucocorticosteroids or flare, escalation, hospitalisation or intestinal resection. To assess healthcare utilisation, we recorded the number of outpatient clinic attendances and investigations. We also collected anxiety, depression and somatoform symptom scores and quality of life scores during follow-up.
Results: Among 125 individuals with Rome III data at all three time points, only 41 (32.8%) never reported IBS-type symptoms. Fifteen patients (12.0%) had IBS-type symptoms at baseline that resolved, 19 (15.2%) had fluctuating symptoms, 35 (28.0%) had new-onset symptoms, and 15 (12.0%) had persistent symptoms. Among more than 300 patients with IBD activity data, IBS-type symptoms were not associated with an increased likelihood of the need for glucocorticosteroids or flare, escalation, hospitalisation or intestinal resection. However, the mean numbers of outpatient appointments and endoscopic investigations were significantly higher among those with IBS-type symptoms. Anxiety, depression and somatoform symptom scores were significantly higher, and quality of life scores were significantly lower, in those reporting IBS-type symptoms at least once during the study.
Conclusions: IBS-type symptoms affected more than two-thirds of patients with IBD during >6 years of follow-up and were associated with increased healthcare utilisation, and worse anxiety, depression, somatoform symptom and quality of life scores, but not adverse disease activity outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apt.17193 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Inflammatory bowel disease (IBD) causes fatigue, pain and faecal urgency/incontinence symptoms. Identifying symptom profile subgroups and related psychological correlates might enable earlier intervention and more effective tailored treatment pathways.
Methods: This study was nested within a randomised controlled trial of a digital symptom intervention for people with IBD (n=780).
The prevalence of small intestine bacterial overgrowth in irritable bowel syndrome is much higher with lactulose than glucose breath test: Results of a retrospective monocentric study.
Clin Res Hepatol Gastroenterol
November 2024
Hospices Civils de Lyon, Service de Biochimie et Biologie Moléculaire, Pierre Bénite, France.
Article Synopsis
- The study aimed to determine if lactulose breath tests (LBT) are more effective than glucose breath tests (GBT) for diagnosing small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome (IBS) patients.
- Among 287 IBS patients analyzed, LBT showed a significantly higher prevalence of SIBO at 47% compared to just 4.5% for GBT, indicating that the tests are not interchangeable.
- Despite the different SIBO prevalence rates, neither test showed a correlation with the severity of IBS symptoms, suggesting limited clinical usefulness for diagnosing SIBO in these patients.
Review article: The role of the gut-brain axis in inflammatory bowel disease and its therapeutic implications.
Aliment Pharmacol Ther
November 2024
Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
Background: Treatments targeting the gut-brain axis (GBA) are effective at reducing symptom burden in irritable bowel syndrome (IBS). The prevalence of common mental disorders and IBS-type symptom reporting is significantly higher in inflammatory bowel disease (IBD) than would be expected, suggesting potential GBA effects in this setting. Manipulation of the GBA may offer novel treatment strategies in selected patients with IBD.
View Article and Find Full Text PDFMast Cell Activation Syndrome and Gut Dysfunction: Diagnosis and Management.
Curr Gastroenterol Rep
April 2024
Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Purpose Of Review: Mast cell activation syndrome (MCAS) is a clinical disorder that may explain irritable bowel syndrome (IBS) type symptoms as well as other allergic symptoms experienced by an individual. The diagnosis and treatment of MCAS with specific focus on gastrointestinal (GI) manifestations is reviewed.
Recent Findings: Although biomarkers for MCAS remain elusive, testing for baseline serum tryptase will distinguish the type of mast cell disorder and urine tests for mast cell mediator metabolites may support the diagnosis.
PMA - Zeolite (Clinoptilolite) in the Management of Irritable Bowel Syndrome - a Non-Interventional Study.
Z Gastroenterol
March 2024
KIM III/Gastroenterol., MedUniWien, Vienna, Austria.
Unlabelled: In clinical practice, the treatment of patients with irritable bowel syndrome (IBS) can be very challenging. The aims of the present non-interventional study (NIS) were to investigate the tolerability and efficacy of PMA-zeolite under everyday conditions in patients with diarrheic IBS type (IBS-D) or constipated type (IBS-C) or mixed type (IBS-M).
Methods: To document prospective data on tolerability and symptom frequency in the frame of a nationwide NIS, we recruited 204 IBS patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!